Chester County News and Community Website
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently announced the resolution of its patent litigation against Lupin Limited regarding a generic version of WAKIX® (pitolisant hydrochloride). The …
Harmony Biosciences Reaches Settlement with Lupin Over WAKIX® Patent Litigation Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced significant advancements in the intellectual property backing its AVIM (Atrioventricular Interval Modulation) therapy pipeline. Over the past year, …
Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation Read More
WASHINGTON, D.C. — A group of bipartisan lawmakers, led by U.S. Senator John Fetterman (D-PA), unveiled the SHIELD Against CCP Act this week to bolster national security measures against threats …
Fetterman Leads Bipartisan Charge to Stop Ccp’s Threats and Fentanyl Crisis Read More
MALVERN, PA — Rajant Health Incorporated (RHI) has been granted a new patent for its innovative Parallel Adaptive Motion Artifact Removal technology, marking a major advancement in wearable health monitoring …
Rajant Health Secures Patent for Cutting-Edge Wearable Monitoring Technology Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has secured its fifth U.S. patent for QTORIN™ 3.9% rapamycin anhydrous gel, reinforcing its position in the development of treatments for rare …
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin Read More
PHOENIXVILLE, PA — PleoPharma, Inc. has announced a significant intellectual property milestone with the issuance of its third U.S. patent, aimed at addressing sleep disturbances linked to cannabis withdrawal syndrome …
PleoPharma Secures Patent for Treating Sleep Disturbances in Cannabis Withdrawal Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has announced significant advancements in its intellectual property portfolio, reinforcing the company’s leadership in the development of DNA Damage Response (DDR) therapeutics for …
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation Read More